At a glance
| Trade context | SYN-AKE |
|---|---|
| Material identity | Synthetic peptide mimic |
| Research inspiration | Waglerin-1 functionality |
| Studied outcomes | Expression-line and skin-texture appearance |
| Evidence limitation | Supplier and multi-ingredient product data |
Overview
The long ingredient name identifies a specific synthetic molecule, while SYN-AKE identifies a commercial ingredient preparation. It is not whole snake venom. The manufacturer describes functional inspiration from waglerin-1, but inspiration is not chemical identity or proof of comparable effects in intact human skin. The cosmetic claim concerns expression-line appearance. Evaluating it requires separating supplier-sponsored evidence, peer-reviewed research on finished products, and the behavior of the isolated compound. A serum may contain this ingredient alongside another peptide, exfoliating or hydrating agents, and botanical components, so an improvement after use does not identify the contribution of SYN-AKE alone.
How it works
The proposed concept is modulation of neuromuscular signaling inspired by waglerin-related activity. The supplier reports laboratory contraction studies and cosmetic tests. Whether a topical preparation reaches a relevant site at an effective exposure is a separate issue from observing an effect in a laboratory preparation. This proposed mechanism should not be described as clinically equivalent to the enzymatic action and injection delivery of botulinum toxin.
Supplier evidence and published product evidence
The manufacturer describes a placebo-comparison cosmetic study involving one hundred volunteers across four groups. This is sponsor-reported information, not independently replicated proof. A 2026 publication also studied a serum containing this ingredient, acetyl hexapeptide-8, gluconolactone, niacinamide, and laminaria extract. That design evaluates the serum, not each active ingredient separately.
Why a combination result cannot identify one active
The published serum work combined ex vivo measurements with clinical assessments of wrinkles and texture. Even if those changes are valid, several ingredients and the base formulation could contribute. Establishing the isolated peptide’s effect would require a matched comparison that differs only in that component, with appropriate blinding and objective outcomes.
Supporting sources [2]
Keep the topical scope explicit
Cosmetic status is not FDA drug approval. Supplier descriptions of topical suitability cannot be extrapolated to injection, untested raw material, or arbitrary reformulations. Tolerability should be assessed for the finished product and intended use; a venom-inspired marketing story does not quantify either benefit or risk.
Reading this profile
Jurisdiction: United States; status and indications may differ elsewhere. Molecular class: Synthetic peptide-mimetic cosmetic ingredient.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- dsm-firmenich: SYN-AKE ingredient, proposed action, and supplier studies ↗Manufacturer / sponsor · Checked 2026-10-27
- Multi-active peptide serum: ex vivo and clinical studies ↗Clinical trial source · Checked 2026-10-27
- FDA: authority over cosmetics and the distinction from drug approval ↗Regulatory source · Checked 2026-10-27